4342-03-4 Dacarbazine

Superiority:

Product Name: Dacarbazine
Synonyms: (5E)-5-(dimethylaminohydrazinylidene)-4-imidazolecarboxamide;(dimethyltriazeno)imidazolecarboxamide;4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide;4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide;5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamid;(E)-5-(3,3-diMethyltriaz-1-en-1-yl)-1H-iMidazole-4-carboxaMide;Dacarbazine, 98.0%(LC&T;Dacarbazine SynonyMs 5-(3,3-DiMethyl-1-triazenyl)iMidazole-4-carboxaMide
CAS: 4342-03-4
MF: C6H10N6O
MW: 182.18
EINECS: 224-396-1
Product Categories: DELALUTIN;Pharmaceutical;Active Pharmaceutical Ingredients;Antitumors for Research and Experimental Use;Biochemistry;API's;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File: 4342-03-4.mol

Dacarbazine Chemical Properties
Melting point  199-205°C
Boiling point  315.57°C (rough estimate)
density  1.3206 (rough estimate)
refractive index  1.7500 (estimate)
storage temp.  2-8°C
solubility  Slightly soluble in water and in anhydrous ethanol, practically insoluble in methylene chloride.
form  powder
pka pKa 4.42 (Uncertain)
Water Solubility  Slightly soluble in water, DMSO and ethanol /n
Merck  14,2798
CAS DataBase Reference 4342-03-4(CAS DataBase Reference)
EPA Substance Registry System Dacarbazine (4342-03-4)
Safety Information
Hazard Codes  T,Xi,Xn
Risk Statements  45-46-20/21/22-36/37/38
Safety Statements  53-36/37/39-45-37/39-36-26
WGK Germany  3
RTECS  NI3950000
HS Code  29349990
Hazardous Substances Data 4342-03-4(Hazardous Substances Data)

Dacarbazine Usage And Synthesis
Antineoplastic drug Dacarbazine is a new type of purine precursor-class anticancer drug. It can interfere with purine biosynthesis, while having the role of alkylating agents together. It has inhibitory effects on mice sarcoma-180, lung cancer-755, melanoma B16 and leukemia L-1210. It takes effects on the G2 phase of the cell cycle with its main impact on RNA and protein synthesis, followed by DNA. Its oral absorption is not complete with large individual differences. After single-time intravenous injection, it reaches peak within 30 min and disappear after 6h. During the 6 h, the drug excreted from urine account for 30% of the total administered dose. It can’t penetrate through the blood-brain barrier.
Clinical cases mainly apply the citrate salt form of dacarbazine that appears as a white crystalline powder. Its aqueous solution exhibits strong acidicity with the pH being 1.9 to 2.3. It is mainly used for the treatment of malignant melanoma with a better efficacy than hydroxyurea. When being used in combination with vinblastine and BCNU, its efficacy can be improved. It can also be applied to the treatment of squamous cell carcinoma and undifferentiated carcinoma, leiomyosarcoma, fibrosarcoma and so on. However, it is ineffective in treating digestive tract tumors.
Pharmacodynamics Dacarbazine is the structural analog of the precursor of the purine biosynthesis (see Figure 1), but with its biological effect being similar to the alkylating agent and belongs to the cell cycle non-specific drugs. It has inhibitory effects on several kinds of animal tumors with its major effects on in the G2 phase of the cell cycle with the inhibitory effect being more significant than RNA and protein synthesis.